Phase 1 Tic disorder Clinical Trials
7 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–7 of 7 trials
Recruiting
Phase 1
A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma
NeoplasmLymphoproliferative DisordersNeoplasms by Histologic Type+11 more
Kelonia Therapeutics, Inc.70 enrolled7 locationsNCT07075185
Not Yet Recruiting
Phase 1
A Phase 1, Open-label. First-in Human Study to Examine the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary Efficacy of OZ-001 when Administered Orally in Adults with Solid Tumours with a Focus on Triple Negative Breast Cancer (Phase 1b)
Neoplastic Disorders
Oncozen Co.. Ltd5 enrolled1 locationACTRN12625000312448
Not Yet Recruiting
Phase 1
A Phase 1, Open-label, First-in Human Study to Examine the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary Efficacy of OZ-001 when Administered Orally in Adults with Solid Tumours with a Focus on Triple Negative Breast Cancer (Phase 1a)
Neoplastic Disorders
Oncozen Co., Ltd18 enrolled1 locationACTRN12625000163404
Recruiting
Phase 1
Add-on MEmaNtine to Dopamine Modulation to Improve Negative Symptoms at First Psychosis
PsychosisNegative Symptoms With Primary Psychotic Disorder
Bjorn H. Ebdrup46 enrolled1 locationNCT04789915
Recruiting
Phase 1
A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study
NeoplasmsMultiple MyelomaCardiovascular Diseases+11 more
OriCell Therapeutics Co., Ltd.81 enrolled1 locationNCT06271252
Terminated
Phase 1
A Study To Determine The Safety, Tolerability, Pharmacokinetics And Recommended Phase 2 Dose Of CCX559 In patients With Solid Tumors
Neoplastic Disorder - Solid Tumors
ChemoCentryx, Inc90 enrolled4 locationsACTRN12621001342808
Completed
Phase 1
Open-Label Study in Healthy Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of Switching from Oral Risperidone to Risperidone Implant (DLP-114)
SchizophreniaBipolar Disorder IAutistic Disorder
Delpor Australia Pty Ltd17 enrolled1 locationACTRN12617001251314